Vandetanib | MedChemExpress (MCE)-产品咨询-资讯-生物在线

Vandetanib | MedChemExpress (MCE)

作者:MedChemExpress LLC 暂无发布时间 (访问量:1149)

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。

Vandetanib

CAS No. : 443913-73-3

MCE 国际站:Vandetanib

产品活性:Vandetanib (D6474) 是一种有效的,具有口服活性的 VEGFR2/KDR 酪氨酸激酶抑制剂 (IC50=40 nM)。Vandetanib 也抑制 VEGFR3/FLT4 (IC50=110 nM) 和 EGFR/HER1 (IC50=500 nM)。

研究领域:Protein Tyrosine Kinase/RTK  |  Autophagy  |  Apoptosis

作用靶点:VEGFR  |  Autophagy  |  Apoptosis

In Vitro: Vandetanib inhibits VEGFR3 and EGFR with IC50 of 110 nM and 500 nM, respectively. Vandetanib is not sensitive to PDGFRβ, Flt1, Tie-2 and FGFR1 with IC50 of 1.1-3.6 μM, while almost has no activity against MEK, CDK2, c-Kit, erbB2, FAK, PDK1, Akt and IGF-1R with IC50 above 10 μM. Vandetanib inhibits VEGF-, EGF- and bFGF-stimulated HUVEC proliferation with IC50 of 60 nM, 170 nM and 800 nM, with no effect on basal endothelial cell growth. Vandetanib inhibits tumor cell growth with IC50 of 2.7 μM (A549) to 13.5 μM (Calu-6). Odanacatib is a weak inhibitor of antigen presentation, measured in a mouse B cell line (IC50=1.5±0.4 μM), compared to the Cat S inhibitor LHVS (IC50=0.001 μM) in the same assay. Odanacatib also shows weak inhibition of the processing of the MHC II invariant chain protein Iip10 in mouse splenocytes compared to LHVS (minimum inhibitory concentration 1-10 μM versus 0.01 μM, respectively). Vandetanib suppresses phosphorylation of VEGFR-2 in HUVECs and EGFR in hepatoma cells and inhibits cell proliferation.

In Vivo: Vandetanib (15 mg/kg, p.o.) has a superior anti-tumor effect than gefitinib in the H1650 xenograft model, and suppresses tumor growth with IC50 of 3.5±1.2 μM. In tumor-bearing mice, vandetanib (50 or 75 mg/kg) suppresses phosphorylation of VEGFR-2 and EGFR in tumor tissues, significantly reduces tumor vessel density, enhances tumor cell apoptosis, suppresses tumor growth, improves survival, reduces number of intrahepatic metastases, and upregulates VEGF, TGF-α, and EGF in tumor tissues.

相关产品:Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Apoptosis Compound Library  |  Kinase Inhibitor Library  |  Protein Tyrosine Kinase Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  CNS-Penetrant Compound Library  |  Autophagy Compound Library  |  Drug Repurposing Compound Library  |  Differentiation Inducing Compound Library  |  Reprogramming Compound Library  |  Orally Active Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Anti-Breast Cancer Compound Library  |  Anti-Lung Cancer Compound Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  Targeted Therapy Drug Library   |  Angiogenesis-Related Compound Library  |  Anti-Liver Cancer Compound Library   |  Rare Diseases Drug Library  |  Anti-Colorectal Cancer Compound Library   |  EMA-Approved Drug Library  |  FDA-Approved Anticancer Drug Library  |  Anti-Prostate Cancer Compound Library  |  Anti-Pulmonary Fibrosis Compound Library  |  Heterocyclic Compound Library  |  Withdrawn Drug Compound Library  |  Off-patent Drug Library  |  Membrane Protein-targeted Compound Library  |  Membrane Receptor-targeted Compound Library  |  Cytokine Inhibitors Library  |  Cell Death Library  |  Anti-Hematopathy Compound Library  |  Anti-Ovarian Cancer Compound Library  |  Multi-Target Compound Library  |  Bioactive Compound Library Max  |  Anti-Gastric Cancer Compound Library  |  MG-132  |  Doxorubicin hydrochloride  |  Bafilomycin A1  |  Tamoxifen  |  Y-27632  |  Paclitaxel  |  Z-VAD-FMK  |  LY294002  |  2-Deoxy-D-glucose  |  Angiotensin II human  |  Acetylcysteine  |  Staurosporine  |  Actinomycin D  |  SB-431542  |  5-Fluorouracil  |  Bortezomib  |  Oxaliplatin  |  Deferoxamine mesylate  |  Sorafenib  |  Trametinib  |  Gemcitabine  |  Temozolomide  |  Etoposide  |  Rotenone  |  Mdivi-1  |  Monomethyl auristatin E  |  Decitabine  |  Ruxolitinib  |  Elesclomol  |  DAPT

热门产品线:重组蛋白  |  药物筛选  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products:Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库,我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物;
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域;
•   产品种类涵盖各种重组蛋白,多肽,常用试剂盒 ,更有 PROTAC、ADC 等特色产品,广泛应用于新药研发、生命科学等科研项目;
•   提供虚拟筛选,离子通道筛选,代谢组学分析检测分析,药物筛选等专业技术服务;
•   设有专业的实验中心和严格的质控、验证体系;
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告,确保产品的高纯度、高品质;
•   产品的生物活性多经各国客户实验验证;
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果;
•   专业团队跟踪最新的制药及生命科学研究进展,为您提供全球最新的活性化合物;
•   与世界各大制药公司及知名科研机构建立了长期的合作。

类药多样性化合物库
顾客使用MCE产品发表的科研文献
一站式药筛新体验
MCE 您身边的生物活性分子大师 | 抑制剂、激动剂、化合物库
重组蛋白 | 高纯度、高稳定性
磁珠
MCE Hotline: 4008203792 | 中国现货 - 全球文献引用 - 高纯度高品质 - 全方位技术支持
MedChemExpress LLC 商家主页

地 址: 上海市浦东新区张衡路1999弄3号楼

联系人: 销售部

电 话: 021-58955995

传 真: 021-53700325

Email:sales@medchemexpress.cn

相关咨询
ADVERTISEMENT